Rhythm Pharmaceuticals (RYTM) Q1 2025 earnings summary

Executive summary

• Q1 2025 product revenue reached $37.7 million, up 45% year-over-year, driven by strong IMCIVREE demand and international expansion, with a 14% increase in reimbursed therapy patients quarter-over-quarter.

• The pivotal Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity (HO) met its primary endpoint, showing a -19.8% placebo-adjusted BMI reduction at 52 weeks, with consistent efficacy across age groups and no new safety signals.

• Net loss attributable to common stockholders narrowed to $49.5 million–$50.8 million from $141.4 million in Q1 2024, reflecting lower R&D expenses and higher revenue.

• Cash, cash equivalents, and short-term investments totaled $314.5 million at quarter-end, expected to fund operations into 2027.

• Reacquired IMCIVREE rights in China, Hong Kong, and Macau after terminating the RareStone Group agreement; strategy for Asia under evaluation.

Financial highlights

• Q1 2025 net product revenue: $37.7 million, up from $26.0 million in Q1 2024; U.S. revenue was $24.4–$24.5 million, international revenue $13.2–$13.3 million.

• Net loss per share (GAAP): $0.81 for Q1 2025, compared to $2.35 in Q1 2024.

• R&D expenses: $37.0 million, down significantly year-over-year; SG&A: $39.1 million, up modestly.

• Cash used in operations: $40.4 million in Q1 2025, reflecting seasonal bonus payments.

• License revenue was negative ($5.0 million) due to the RareStone agreement termination.

Outlook and guidance

• Regulatory submissions for setmelanotide in acquired HO are on track for Q3 2025 in both the U.S. and EU.

• Anticipates $285–$315 million in non-GAAP operating expenses for 2025, with SG&A of $135–$145 million and R&D of $150–$170 million.

• Cash runway expected to support operations into 2027, beyond key clinical and regulatory milestones.

• Topline data from Phase 2 oral bivamelagon in acquired HO expected in Q3 2025; updates on Prader-Willi and RM-718 studies by year-end.